SITAGLIPTIN, A DIPEPTIDYL PEPTIDASE-4 INHIBITOR, CAN PREVENT THE EXPRESSION OF OXIDATIVE STRESS DUE TO DECREASING SERUM FERRITIN LEVEL.

被引：0
|
作者：
Fukunishi, Shinya [1 ]
Yokohama, Keisuke [1 ]
Nakamura, Ken [1 ]
Ohama, Hideko [1 ]
Tsuchimoto, Yusuke [1 ]
Okamoto, Norio [1 ]
Matsui, Masahiro [1 ]
Yasuoka, Hidetaka [1 ]
Nishikawa, Tomohiro [1 ]
Asai, Akira [1 ]
Higuchi, Kazuhide [1 ]
机构：
[1] Osaka Med Coll, Dept Internal Med 2, Osaka, Japan
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2271
引用
收藏
页码：1335A / 1335A
页数：1
相关论文
共 50 条
  • [21] Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
    Hanefeld, Markolf
    Herman, Gary A.
    Wu, Mei
    Mickel, Carolyn
    Sanchez, Matilde
    Stein, Peter P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1329 - 1339
  • [22] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    I. Raz
    M. Hanefeld
    L. Xu
    C. Caria
    D. Williams-Herman
    H. Khatami
    Diabetologia, 2006, 49 : 2564 - 2571
  • [23] NEPHROPATHY EVOLUTION IS PREVENTED BY THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR, SITAGLIPTIN, IN A RAT MODEL OF TYPE 2 DIABETES
    Mega, Cristina
    Reis, Flavio
    de Lemos, Edite Teixeira
    Vala, Helena
    Fernandes, Rosa
    Oliveira, Jorge
    Teixeira, Frederico
    Reis, Flavio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 160 - 160
  • [24] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    Raz, I.
    Hanefeld, M.
    Xu, L.
    Caria, C.
    Williams-Herman, D.
    Khatami, H.
    DIABETOLOGIA, 2006, 49 (11) : 2564 - 2571
  • [25] Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    Aschner, Pablo
    Kipnes, Mark S.
    Lunceford, Jared K.
    Sanchez, Matilde
    Mickel, Carolyn
    Williams-Herman, Debora E.
    DIABETES CARE, 2006, 29 (12) : 2632 - 2637
  • [26] Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Indomethacin-Induced Intestinal Mucosal Injury in Rats
    Fujiwara, Kaori
    Inoue, Takuya
    Narabayashi, Ken
    Sakanaka, Taisuke
    Okada, Toshihiko
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Kuramoto, Takanori
    Ishida, Kumi
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Tokioka, Satoshi
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2013, 144 (05) : S716 - S716
  • [27] The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice
    Yorifuji, Naoki
    Inoue, Takuya
    Iguchi, Munetaka
    Fujiwara, Kaori
    Kakimoto, Kazuki
    Nouda, Sadaharu
    Okada, Toshihiko
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Higuchi, Kazuhide
    ONCOLOGY REPORTS, 2016, 35 (02) : 676 - 682
  • [28] Potential Role of Dipeptidyl Peptidase-4 in Regulating Mitochondria and Oxidative Stress in Cardiomyocytes
    Lee, Shih-Yi
    Wu, Shao-Tung
    Du, Chen-Xuan
    Ku, Hui-Chun
    CARDIOVASCULAR TOXICOLOGY, 2024, 24 (10) : 1090 - 1104
  • [29] The Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Suppresses Mouse Colon Tumorigenesis in Type 2 Diabetes Mice
    Yorifuji, Naoki
    Inoue, Takuya
    Fujiwara, Kaori
    Iguchi, Munetaka
    Kojima, Yuichi
    Okada, Toshihiko
    Kakimoto, Kazuki
    Nouda, Sadaharu
    Kawakami, Ken
    Abe, Yosuke
    Takeuchi, Toshihisa
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2015, 148 (04) : S577 - S577
  • [30] Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
    Mistry, Goutam C.
    Maes, Andrea L.
    Lasseter, Kenneth C.
    Davies, Michael J.
    Gottesdiener, Keith M.
    Wagner, John A.
    Herman, Gary A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (05): : 592 - 598
12345